FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036069351> ?p ?o ?g. }

• W3036069351 endingPage "1466" @default.
• W3036069351 startingPage "1466.2" @default.
• W3036069351 abstract "Background: The goal of treatment with biological DMARDs (bDMARDs) should be the use for a limited period of time, during the called “therapeutic window of opportunity” to induce disease remission, followed by the maintenance of low activity with conventional DMARDs. We study if we achieve this goal in a cohort of patients treated by objectives in the last 6 years. Objectives: To assess the frequency and characteristics of patients with rheumatoid arthritis (RA), spondyloarthropathies (SA) and psoriatic arthritis (PsA)) treated with FB / SD who achieve remission without FB / SD. Methods: Observational and prospective study, which included a cohort of patients with RA, SA and PsA treated by objectives with FB / SD and optimized from January 2014 to December 2019. Optimization, defined as the reduction or prolongation of the interval of at least one dose, it was indicated when patients had received> 6 months of treatment and were in clinical remission / low activity defined as DAS28 <3.2 for RA and PsA, and BASDAI <4 for SpA. All patients who managed to maintain remission without receiving FB / SD were also collected. Results: A total of 260 patients (115 RA, 69 SA and 76 PsA) were included in the study. Of the total of these patients, 32.7% received at least two treatments (“switch”). Of all the patients, 53% were optimized and according to the diagnosis: 60.9% had RA, 52.2% SA and 39.4% PsA. 5.3% of the patients were free of FB / SD: 5 patients with RA (4.34%), 8 patients with SA (11.6%) and 1 patient with PsA (1.3%). Among patients who entered clinical remission without FB / SD, 57% had received only one treatment with FB / SD while 43% of the patients had received two or more FB / SD. Only 3 of the patients with RA and 1 patient with PsA managed to be free of treatment without FB / SD or conventional DMARD. Conclusion: Remission without FB / SD treatment was rare, being higher in SA than in RA and in PsA, maintaining the same severity and frequency patterns in achieving optimization according to different pathologies (EspA> AR> APs). Except in the APs, more than 50% of the patients with RA and SA entered into optimization. Clinical remission without FB / SD was less frequent in the PsA probably because the MDA is more demanding than the other outcome measures and because it is a more complex and heterogeneous disease with domains controlled by various cytokines. Patients with disease-free RA or APs without FB / SD or conventional DMARD were the exception. Disclosure of Interests: None declared" @default.
• W3036069351 created "2020-06-25" @default.
• W3036069351 creator A5020785051 @default.
• W3036069351 creator A5038348871 @default.
• W3036069351 date "2020-06-01" @default.
• W3036069351 modified "2023-09-25" @default.
• W3036069351 title "AB0335 PATIENTS IN REMISSION FREE OF DIRECTED BIOLOGICAL / SYNTHETIC DRUG. ANALYSIS OF A COHORT OF PATIENTS TREATED BY OBJECTIVES IN OPTIMIZATION FOR 6 YEARS" @default.
• W3036069351 doi "https://doi.org/10.1136/annrheumdis-2020-eular.5382" @default.
• W3036069351 hasPublicationYear "2020" @default.
• W3036069351 type Work @default.
• W3036069351 sameAs 3036069351 @default.
• W3036069351 citedByCount "0" @default.
• W3036069351 crossrefType "journal-article" @default.
• W3036069351 hasAuthorship W3036069351A5020785051 @default.
• W3036069351 hasAuthorship W3036069351A5038348871 @default.
• W3036069351 hasBestOaLocation W30360693511 @default.
• W3036069351 hasConcept C126322002 @default.
• W3036069351 hasConcept C141071460 @default.
• W3036069351 hasConcept C188816634 @default.
• W3036069351 hasConcept C201903717 @default.
• W3036069351 hasConcept C2776260265 @default.
• W3036069351 hasConcept C2777226972 @default.
• W3036069351 hasConcept C2777453003 @default.
• W3036069351 hasConcept C2777575956 @default.
• W3036069351 hasConcept C44249647 @default.
• W3036069351 hasConcept C71924100 @default.
• W3036069351 hasConcept C72563966 @default.
• W3036069351 hasConceptScore W3036069351C126322002 @default.
• W3036069351 hasConceptScore W3036069351C141071460 @default.
• W3036069351 hasConceptScore W3036069351C188816634 @default.
• W3036069351 hasConceptScore W3036069351C201903717 @default.
• W3036069351 hasConceptScore W3036069351C2776260265 @default.
• W3036069351 hasConceptScore W3036069351C2777226972 @default.
• W3036069351 hasConceptScore W3036069351C2777453003 @default.
• W3036069351 hasConceptScore W3036069351C2777575956 @default.
• W3036069351 hasConceptScore W3036069351C44249647 @default.
• W3036069351 hasConceptScore W3036069351C71924100 @default.
• W3036069351 hasConceptScore W3036069351C72563966 @default.
• W3036069351 hasIssue "Suppl 1" @default.
• W3036069351 hasLocation W30360693511 @default.
• W3036069351 hasOpenAccess W3036069351 @default.
• W3036069351 hasPrimaryLocation W30360693511 @default.
• W3036069351 hasRelatedWork W1997363697 @default.
• W3036069351 hasRelatedWork W2023378412 @default.
• W3036069351 hasRelatedWork W2049821801 @default.
• W3036069351 hasRelatedWork W2111965497 @default.
• W3036069351 hasRelatedWork W2171255147 @default.
• W3036069351 hasRelatedWork W2328099609 @default.
• W3036069351 hasRelatedWork W2414197351 @default.
• W3036069351 hasRelatedWork W2617521628 @default.
• W3036069351 hasRelatedWork W2908842928 @default.
• W3036069351 hasRelatedWork W3042515300 @default.
• W3036069351 hasVolume "79" @default.
• W3036069351 isParatext "false" @default.
• W3036069351 isRetracted "false" @default.
• W3036069351 magId "3036069351" @default.
• W3036069351 workType "article" @default.